鲁抗医药(600789) - 2024 Q3 - 季度财报

Financial Performance - Revenue for Q3 2024 was CNY 1,387,475,715.63, a decrease of 10.24% compared to the same period last year[2] - Net profit attributable to shareholders was CNY 47,096,083.43, down 23.01% year-over-year[2] - Basic earnings per share for the period was CNY 0.05, a decrease of 23.73% compared to the same period last year[2] - Total operating revenue for the first three quarters of 2024 was approximately ¥4.67 billion, a slight decrease of 1.37% compared to ¥4.73 billion in the same period of 2023[14] - Net profit for the first three quarters of 2024 reached approximately ¥356.92 million, an increase of 78.67% compared to ¥199.95 million in the same period of 2023[15] - Basic earnings per share for the first three quarters of 2024 were ¥0.39, up from ¥0.22 in the same period of 2023[16] - The company reported an operating profit of approximately ¥372.54 million for the first three quarters of 2024, compared to ¥221.18 million in the same period of 2023, reflecting a significant increase[15] - The total profit for the first three quarters of 2024 was approximately ¥372.33 million, up from ¥221.84 million in the same period of 2023[15] Assets and Liabilities - Total assets at the end of the reporting period were CNY 9,150,038,995.15, an increase of 3.95% from the end of the previous year[3] - Shareholders' equity attributable to the parent company was CNY 3,893,469,477.55, up 7.80% year-over-year[3] - The company's current assets reached RMB 4,203,339,916.12, up from RMB 3,647,794,413.96 at the end of 2023, indicating an increase of about 15.2%[11] - Total liabilities as of September 30, 2024, were RMB 5,117,055,366.50, slightly up from RMB 5,061,083,122.05 at the end of 2023, indicating a growth of approximately 1.1%[12] - The company's equity attributable to shareholders increased to RMB 3,893,469,477.55 from RMB 3,611,695,001.53, representing a growth of about 7.8%[13] - The long-term borrowings increased to RMB 1,362,826,000.00 from RMB 1,308,926,000.00, reflecting an increase of approximately 4.1%[12] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 404,714,257.80, down 12.13% compared to the same period last year[2] - The net cash flow from operating activities for Q3 2024 was CNY 404,714,257.80, a decrease of 12.1% compared to CNY 460,575,170.99 in Q3 2023[18] - Total cash inflow from operating activities was CNY 3,786,030,177.32, while cash outflow was CNY 3,381,315,919.52, resulting in a net cash inflow of CNY 404,714,257.80[18] - Cash flow from investing activities showed a net outflow of CNY 176,726,176.10, compared to a larger outflow of CNY 285,793,797.11 in the same period last year[18] - Cash inflow from financing activities totaled CNY 921,355,157.81, a decrease from CNY 1,741,939,495 in Q3 2023[19] - The net cash flow from financing activities was negative at CNY -188,301,912.41, compared to CNY -147,226,864.60 in the previous year[19] - The ending balance of cash and cash equivalents increased to CNY 575,424,936.99, up from CNY 415,809,810.33 in Q3 2023[19] - The company paid CNY 149,846,940.61 in dividends and interest during the quarter, compared to CNY 120,986,220.08 in the same period last year[19] - The cash paid to employees increased to CNY 517,618,570.09, up from CNY 485,526,932.41 in Q3 2023[18] Other Financial Metrics - Non-recurring gains and losses for the period totaled CNY 5,341,840.54, with a cumulative amount of CNY 213,625,242.20 for the year-to-date[4] - The weighted average return on equity was 1.30%, a decrease of 0.51 percentage points from the previous year[3] - Research and development expenses for the first three quarters of 2024 were approximately ¥223.17 million, a decrease of 2.20% from ¥229.68 million in the same period of 2023[14] - Other income for the first three quarters of 2024 was approximately ¥108.18 million, an increase of 90.73% compared to ¥56.74 million in the same period of 2023[15] - The company experienced a decrease in sales expenses, which were approximately ¥422.55 million in the first three quarters of 2024, down from ¥453.41 million in the same period of 2023, representing a reduction of 6.78%[14] - The impact of exchange rate changes on cash and cash equivalents was CNY 5,692,870.33, compared to CNY 1,216,731.87 in Q3 2023[19]